Immune Pharmaceuticals Partners in Antibody DevelopmentBy
Immune Pharmaceuticals, a New York-headquartered clinical-stage biopharmaceutical company focused on inflammatory diseases and cancers, has entered into an exclusive sub-license agreement with SATT Sud-Est, a Marseille, France-based technology transfer office, to develop, use, manufacture, and commercialize mono- and bispecific antibodies targeting components of the tumor microenvironment and angiogenic factors.
The research program will be carried out under the responsibility of several entities, including: the Institut national de la santé et de la recherche médicale, a public scientific and technological organization under the dual supervision of the Ministry of Health and the Ministry of Research in France; the National Center for Scientific Research in France; the University Cote d’Azur; the Scientific Center of Monaco; and Immune Pharmaceuticals.
The research project is based on a technology platform for producing tetravalent immunoglobuin G-1-like bispecific antibodies, developed by Dr. Jean Kadouche, scientific co-founder of Immune, with a European academic consortium under a European Commission grant. This collaboration will leverage the scientific and technological expertise of several scientists and will be led by Gilles Pagès, principal investigator in the Institute for Research on Cancer and Aging of Nice, France.
Under the agreement, Immune Pharmaceuticals will fund the development of the bispecific program, including the tumor microenvironment project, through its subsidiary, Cytovia Oncology. The targets of the bispecific antibodies are known vascular endothelial growth factor and cytokines of the interleukin-8 family that drive the autocrine proliferation loop in tumor cells, inflammation, and angiogenesis, according to Pagès.
Source: Immune Pharmaceuticals